{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:37:06Z","timestamp":1778038626884,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2022.109650","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T08:14:04Z","timestamp":1673424844000},"page":"109650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A perspective on SARS-CoV-2 virus-like particles vaccines"],"prefix":"10.1016","volume":"115","author":[{"given":"Xiaoyang","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinlan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0760-0503","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0005","first-page":"445","article-title":"SARS-COV2, variants, membranes and basic physics","volume":"206","author":"Binot","year":"2022","journal-title":"Bull. Acad. Natl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109650_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","article-title":"Emerging treatment strategies for COVID-19 infection","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2022.109650_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.intimp.2018.07.011","article-title":"Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28\/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses","volume":"63","author":"Liu","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0020","article-title":"Recent progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0025","article-title":"Anti-influenza protective efficacy of a H6 virus-like particle in chickens","volume":"8","author":"Zhu","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109650_b0035","doi-asserted-by":"crossref","first-page":"e0260331","DOI":"10.1371\/journal.pone.0260331","article-title":"A Putative long-range RNA-RNA interaction between ORF8 and Spike of SARS-CoV-2","volume":"17","author":"Omoru","year":"2022","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.intimp.2022.109650_b0040","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","article-title":"Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics","volume":"20","author":"Petersen","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.109650_b0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11427-021-1964-4","article-title":"Overview of SARS-CoV-2 genome-encoded proteins","volume":"65","author":"Bai","year":"2022","journal-title":"Sci. China Life Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"13","key":"10.1016\/j.intimp.2022.109650_b0055","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109650_b0060","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/EDE.0b013e3181f20977","article-title":"The effective reproduction number of pandemic influenza: prospective estimation","volume":"21","author":"Cowling","year":"2010","journal-title":"Epidemiology"},{"issue":"18","key":"10.1016\/j.intimp.2022.109650_b0065","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3346\/jkms.2021.36.e124","article-title":"Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?","volume":"36","author":"Jia","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2022.109650_b0070","doi-asserted-by":"crossref","unstructured":"S.E. Galloway, P. Paul, D.R. MacCannell, M.A. Johansson, J.T. Brooks, A. MacNeil, R.B. Slayton, S. Tong, B.J. Silk, G.L. Armstrong, M. Biggerstaff, V.G. Dugan, Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021, MMWR Morb Mortal Wkly Rep 70(3) (2021) 95\u201399.","DOI":"10.15585\/mmwr.mm7003e2"},{"key":"10.1016\/j.intimp.2022.109650_b0075","doi-asserted-by":"crossref","unstructured":"T. Wilton, E. Bujaki, D. Klapsa, M. Majumdar, M. Zambon, M. Fritzsche, R. Mate, J. Martin, Rapid increase of SARS-CoV-2 variant B.1.1.7 detected in sewage samples from England between October 2020 and January 2021, mSystems 6(3) (2021) e0035321.","DOI":"10.1128\/mSystems.00353-21"},{"issue":"6575","key":"10.1016\/j.intimp.2022.109650_b0080","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.abl8506","article-title":"Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants","volume":"374","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109650_b0085","doi-asserted-by":"crossref","unstructured":"M. McCallum, A.C. Walls, K.R. Sprouse, J.E. Bowen, L. Rosen, H.V. Dang, A. deMarco, N. Franko, S.W. Tilles, J. Logue, M.C. Miranda, M. Ahlrichs, L. Carter, G. Snell, M.S. Pizzuto, H.Y. Chu, W.C. Van Voorhis, D. Corti, D. Veesler, Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants, bioRxiv (2021).","DOI":"10.1101\/2021.08.11.455956"},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0090","doi-asserted-by":"crossref","DOI":"10.15212\/ZOONOSES-2021-0024","article-title":"Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529)","volume":"1","author":"Qin","year":"2021","journal-title":"Zoonoses"},{"key":"10.1016\/j.intimp.2022.109650_b0095","doi-asserted-by":"crossref","unstructured":"K. Roltgen, S.C.A. Nielsen, O. Silva, S.F. Younes, M. Zaslavsky, C. Costales, F. Yang, O.F. Wirz, D. Solis, R.A. Hoh, A. Wang, P.S. Arunachalam, D. Colburg, S. Zhao, E. Haraguchi, A.S. Lee, M.M. Shah, M. Manohar, I. Chang, F. Gao, V. Mallajosyula, C. Li, J. Liu, M.J. Shoura, S.B. Sindher, E. Parsons, N.J. Dashdorj, N.D. Dashdorj, R. Monroe, G.E. Serrano, T.G. Beach, R.S. Chinthrajah, G.W. Charville, J.L. Wilbur, J.N. Wohlstadter, M.M. Davis, B. Pulendran, M.L. Troxell, G.B. Sigal, Y. Natkunam, B.A. Pinsky, K.C. Nadeau, S.D. Boyd, Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination, Cell 185(6) (2022) 1025\u20131040 e14.","DOI":"10.1016\/j.cell.2022.01.018"},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0100","article-title":"Unusual SARS-CoV-2 intrahost diversity reveals lineage superinfection","volume":"8","author":"Dezordi","year":"2022","journal-title":"Microb. Genom."},{"issue":"7854","key":"10.1016\/j.intimp.2022.109650_b0105","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109650_b0110","doi-asserted-by":"crossref","unstructured":"M. Ramanathan, I.D. Ferguson, W. Miao, P.A. Khavari, SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity, Lancet Infect. Dis. 21(8) (2021) 1070.","DOI":"10.1016\/S1473-3099(21)00262-0"},{"key":"10.1016\/j.intimp.2022.109650_b0115","doi-asserted-by":"crossref","unstructured":"M. Ramanathan, I.D. Ferguson, W. Miao, P.A. Khavari, SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity, bioRxiv (2021).","DOI":"10.1101\/2021.02.22.432359"},{"key":"10.1016\/j.intimp.2022.109650_b0120","doi-asserted-by":"crossref","unstructured":"P. Wang, M.S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P.D. Kwong, B.S. Graham, J.R. Mascola, J.Y. Chang, M.T. Yin, M. Sobieszczyk, C.A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang, D.D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, bioRxiv (2021).","DOI":"10.1101\/2021.01.25.428137"},{"key":"10.1016\/j.intimp.2022.109650_b0125","article-title":"Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization","author":"Ho","year":"2021","journal-title":"Res. Sq."},{"issue":"7887","key":"10.1016\/j.intimp.2022.109650_b0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","article-title":"Heavily mutated Omicron variant puts scientists on alert","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109650_b0135","doi-asserted-by":"crossref","unstructured":"M. Hoffmann, P. Arora, R. Gross, A. Seidel, B.F. Hornich, A.S. Hahn, N. Kruger, L. Graichen, H. Hofmann-Winkler, A. Kempf, M.S. Winkler, S. Schulz, H.M. Jack, B. Jahrsdorfer, H. Schrezenmeier, M. Muller, A. Kleger, J. Munch, S. Pohlmann, SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies, Cell 184(9) (2021) 2384\u20132393 e12.","DOI":"10.1016\/j.cell.2021.03.036"},{"key":"10.1016\/j.intimp.2022.109650_b0140","doi-asserted-by":"crossref","unstructured":"D. Zhou, W. Dejnirattisai, P. Supasa, C. Liu, A.J. Mentzer, H.M. Ginn, Y. Zhao, H.M.E. Duyvesteyn, A. Tuekprakhon, R. Nutalai, B. Wang, G.C. Paesen, C. Lopez-Camacho, J. Slon-Campos, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T.S. Walter, D. Skelly, S.F. Lumley, C. Dold, R. Levin, T. Dong, A.J. Pollard, J.C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, S. Belij-Rammerstorfer, S. Gilbert, W. James, M.W. Carroll, P. Klenerman, E. Barnes, S.J. Dunachie, E.E. Fry, J. Mongkolsapaya, J. Ren, D.I. Stuart, G.R. Screaton, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell 184(9) (2021) 2348\u20132361 e6.","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"10.1016\/j.intimp.2022.109650_b0145","article-title":"Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization","volume":"150\u2013151","author":"Guo","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.intimp.2022.109650_b0150","doi-asserted-by":"crossref","unstructured":"T. Funk, A. Pharris, G. Spiteri, N. Bundle, A. Melidou, M. Carr, G. Gonzalez, A. Garcia-Leon, F. Crispie, L. O'Connor, N. Murphy, J. Mossong, A. Vergison, A.K. Wienecke-Baldacchino, T. Abdelrahman, F. Riccardo, P. Stefanelli, A. Di Martino, A. Bella, A. Lo Presti, P. Casaca, J. Moreno, V. Borges, J. Isidro, R. Ferreira, J.P. Gomes, L. Dotsenko, H. Suija, J. Epstein, O. Sadikova, H. Sepp, N. Ikonen, C. Savolainen-Kopra, S. Blomqvist, T. Mottonen, O. Helve, J. Gomes-Dias, C. Adlhoch, C.S. Groups, Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021, Euro Surveill 26(16) (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348"},{"issue":"7","key":"10.1016\/j.intimp.2022.109650_b0155","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-021-01397-4","article-title":"SARS-CoV-2 variants of concern are emerging in India","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109650_b0160","first-page":"1774","article-title":"Progress in research of epidemiologic feature and control of SARS-CoV-2 Delta variant","volume":"42","author":"Du","year":"2021","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"6555","key":"10.1016\/j.intimp.2022.109650_b0165","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.abi7994","article-title":"SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern","volume":"373","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.109650_b0170","doi-asserted-by":"crossref","unstructured":"M. McCallum, J. Bassi, A. Marco, A. Chen, A.C. Walls, J.D. Iulio, M.A. Tortorici, M.J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, E. Cameroni, J.E. Bowen, S.W. Tilles, M.S. Pizzuto, S.B. Guastalla, G. Bona, A.F. Pellanda, C. Garzoni, W.C. Van Voorhis, L.E. Rosen, G. Snell, A. Telenti, H.W. Virgin, L. Piccoli, D. Corti, D. Veesler, SARS-CoV-2 immune evasion by variant B.1.427\/B.1.429, bioRxiv (2021).","DOI":"10.1101\/2021.03.31.437925"},{"key":"10.1016\/j.intimp.2022.109650_b0175","doi-asserted-by":"crossref","unstructured":"W. Ren, X. Ju, M. Gong, J. Lan, Y. Yu, Q. Long, D.J. Kenney, A.K. O'Connell, Y. Zhang, J. Zhong, G. Zhong, F. Douam, X. Wang, A. Huang, R. Zhang, Q. Ding, Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion, mBio 13(2) (2022) e0009922.","DOI":"10.1128\/mbio.00099-22"},{"key":"10.1016\/j.intimp.2022.109650_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663912","article-title":"The spike of SARS-CoV-2: uniqueness and applications","volume":"12","author":"Kumavath","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0185","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jmv.27515","article-title":"Omicron variant genome evolution and phylogenetics","volume":"94","author":"Kandeel","year":"2022","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"Ren","year":"2022","journal-title":"World J. Clin. Cases"},{"issue":"5","key":"10.1016\/j.intimp.2022.109650_b0195","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jmv.27541","article-title":"OMICRON (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear","volume":"94","author":"Thakur","year":"2022","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0200","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/jmv.27491","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!","volume":"94","author":"Gao","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2022.109650_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112011","article-title":"GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2","volume":"142","author":"Tsai","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.intimp.2022.109650_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9102167","article-title":"Severity, pathogenicity and transmissibility of delta and Lambda variants of SARS-CoV-2, toxicity of spike protein and possibilities for future prevention of COVID-19","volume":"9","author":"Moghaddar","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2021.101606","article-title":"The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines","volume":"25","author":"Mohammadi","year":"2021","journal-title":"Braz. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0220","first-page":"25","article-title":"Durability of immune responses to the BNT162b2 mRNA vaccine","volume":"3","author":"Suthar","year":"2022","journal-title":"Med. (N.Y.)"},{"key":"10.1016\/j.intimp.2022.109650_b0225","doi-asserted-by":"crossref","first-page":"e068848","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.intimp.2022.109650_b0230","doi-asserted-by":"crossref","first-page":"e0143721","DOI":"10.1128\/JVI.01437-21","article-title":"Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants","volume":"95","author":"Acharya","year":"2021","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109650_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/v14020383","article-title":"Virus-like particles: measures and biological functions","volume":"14","author":"Bhat","year":"2022","journal-title":"Viruses"},{"issue":"13","key":"10.1016\/j.intimp.2022.109650_b0240","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.7150\/thno.42494","article-title":"A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2022.109650_b0245","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2021","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12951-021-00772-0","article-title":"Modular vaccine platform based on the norovirus-like particle","volume":"19","author":"Lampinen","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0255","doi-asserted-by":"crossref","first-page":"e127042","DOI":"10.5812\/ijpr-127042","article-title":"A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases","volume":"21","author":"Sharifzadeh","year":"2022","journal-title":"Iran. J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1134\/S0026893319030154","article-title":"Virus-like particles as an instrument of vaccine production","volume":"53","author":"Syomin","year":"2019","journal-title":"Mol. Biol."},{"key":"10.1016\/j.intimp.2022.109650_b0265","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2019.00592","article-title":"Immunogenicity of a virus-like-particle vaccine containing multiple antigenic epitopes of toxoplasma gondii against acute and chronic toxoplasmosis in mice","volume":"10","author":"Guo","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109650_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.aivir.2016.09.002","article-title":"Biomedical and catalytic opportunities of virus-like particles in nanotechnology","volume":"97","author":"Schwarz","year":"2017","journal-title":"Adv. Virus Res."},{"issue":"12","key":"10.1016\/j.intimp.2022.109650_b0275","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1021\/acs.molpharmaceut.0c00828","article-title":"The role of virus-like particles in medical biotechnology","volume":"17","author":"Comas-Garcia","year":"2020","journal-title":"Mol. Pharm."},{"issue":"Pt B","key":"10.1016\/j.intimp.2022.109650_b0280","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.intimp.2022.109650_b0285","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/978-1-0716-1884-4_26","article-title":"Production of oral vaccines based on virus-like particles pseudotyped with protozoan-surface proteins","volume":"2410","author":"Rupil","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2022.109650_b0290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109650_b0295","doi-asserted-by":"crossref","first-page":"e0273322","DOI":"10.1371\/journal.pone.0273322","article-title":"Self-assembling protein nanoparticles and virus like particles correctly display beta-barrel from meningococcal factor H-binding protein through genetic fusion","volume":"17","author":"Cappelli","year":"2022","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.intimp.2022.109650_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110217","article-title":"Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens","volume":"38","author":"Read","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2022.109650_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.06.006","article-title":"Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants","volume":"47","author":"Thompson","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0310","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4049\/jimmunol.1701067","article-title":"B cell-intrinsic MyD88 signaling promotes initial cell proliferation and differentiation to enhance the germinal center response to a virus-like particle","volume":"200","author":"Tian","year":"2018","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41541-021-00391-8","article-title":"Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines","volume":"6","author":"Sartorius","year":"2021","journal-title":"npj Vaccines"},{"issue":"11","key":"10.1016\/j.intimp.2022.109650_b0320","article-title":"Sublingual immunization with chimeric C1q\/CD40 ligand\/HIV virus-like particles induces strong mucosal immune responses against HIV","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2022.109650_b0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109650_b0330","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-018-3797-7","article-title":"Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71","volume":"163","author":"Wang","year":"2018","journal-title":"Arch. Virol"},{"issue":"3","key":"10.1016\/j.intimp.2022.109650_b0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12250-018-0030-5","article-title":"Zika virus baculovirus-expressed virus-like particles induce neutralizing antibodies in mice","volume":"33","author":"Dai","year":"2018","journal-title":"Virol. Sin."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2022.109650_b0340","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/1061186X.2020.1793990","article-title":"Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19","volume":"28","author":"Alvi","year":"2020","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0345","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acsnano.0c08430","article-title":"Biomimetic virus-like particles as severe acute respiratory syndrome coronavirus 2 diagnostic tools","volume":"15","author":"Chan","year":"2021","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.intimp.2022.109650_b0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021726118","article-title":"Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance","volume":"118","author":"Kaplan","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2022.109650_b0355","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016175","article-title":"The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles","volume":"296","author":"Boson","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.109650_b0360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jbiotec.2019.10.007","article-title":"Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells","volume":"306","author":"Kato","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.intimp.2022.109650_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198141","article-title":"Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development","volume":"288","author":"Samrat","year":"2020","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.109650_b0370","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2567.2010.03231.x","article-title":"Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice","volume":"130","author":"Lu","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2022.109650_b0375","doi-asserted-by":"crossref","unstructured":"C.Y. Yong, W.P.P. Liew, H.K. Ong, C.L. Poh, Development of virus-like particles-based vaccines against coronaviruses, Biotechnol. Prog. (2022) e3292.","DOI":"10.1002\/btpr.3292"},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0380","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0385","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2020-0035","article-title":"COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics","volume":"11","author":"Amawi","year":"2020","journal-title":"Ther. Deliv."},{"issue":"4","key":"10.1016\/j.intimp.2022.109650_b0390","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01628-17","article-title":"Glycan Shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections","volume":"92","author":"Xiong","year":"2018","journal-title":"J. Virol."},{"issue":"7807","key":"10.1016\/j.intimp.2022.109650_b0395","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2022.109650_b0400","doi-asserted-by":"crossref","first-page":"e08124","DOI":"10.1016\/j.heliyon.2021.e08124","article-title":"PRAK-03202: a triple antigen virus-like particle vaccine candidate against SARS CoV-2","volume":"7","author":"Mazumder","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2022.109650_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100786","article-title":"Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach","volume":"38","author":"Ghorbani","year":"2020","journal-title":"New Microbes New Infect."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0410","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41598-022-04883-y","article-title":"Construction of SARS-CoV-2 virus-like particles in plant","volume":"12","author":"Moon","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.109650_b0415","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 virus-like particles by mammalian expression system","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0420","doi-asserted-by":"crossref","first-page":"21877","DOI":"10.1038\/s41598-020-78656-w","article-title":"Minimal system for assembly of SARS-CoV-2 virus like particles","volume":"10","author":"Swann","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2022.109650_b0425","article-title":"Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 S glycoprotein, S1, or S2 domains","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2022.109650_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.857440","article-title":"A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects rhesus macaques","volume":"13","author":"Volkmann","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0435","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41467-020-20251-8","article-title":"Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity","volume":"12","author":"Fougeroux","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2022.109650_b0440","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"issue":"30","key":"10.1016\/j.intimp.2022.109650_b0445","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1016\/j.vaccine.2022.05.046","article-title":"Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-adjuvanted recombinant plant-derived virus-like particle vaccines","volume":"40","author":"Dube","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2022.109650_b0450","article-title":"Plant-based COVID-19 vaccines: current status, design, and development strategies of candidate vaccines","volume":"9","author":"Maharjan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2022.109650_b0455","doi-asserted-by":"crossref","unstructured":"K.J. Hager, G. Perez Marc, P. Gobeil, R.S. Diaz, G. Heizer, C. Llapur, A.I. Makarkov, E. Vasconcellos, S. Pillet, F. Riera, P. Saxena, P. Geller Wolff, K. Bhutada, G. Wallace, H. Aazami, C.E. Jones, F.P. Polack, L. Ferrara, J. Atkins, I. Boulay, J. Dhaliwall, N. Charland, M.M.J. Couture, J. Jiang-Wright, N. Landry, S. Lapointe, A. Lorin, A. Mahmood, L.H. Moulton, E. Pahmer, J. Parent, A. Seguin, L. Tran, T. Breuer, M.A. Ceregido, M. Koutsoukos, F. Roman, J. Namba, M.A. D'Aoust, S. Trepanier, Y. Kimura, B.J. Ward, V.L.P.S.T. Co, Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine, N. Engl. J. Med. 386(22) (2022) 2084\u20132096.","DOI":"10.1056\/NEJMoa2201300"},{"key":"10.1016\/j.intimp.2022.109650_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107763","article-title":"An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages","volume":"96","author":"Motamedi","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109650_b0465","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10070788","article-title":"A summary of the SARS-CoV-2 vaccines and technologies available or under development","volume":"10","author":"Abdulla","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2022.109650_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198305","article-title":"A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein","volume":"295","author":"Roy","year":"2021","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0475","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2022.109650_b0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12896-018-0466-6","article-title":"A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag\/SpyCatcher protein ligase system","volume":"18","author":"Alam","year":"2018","journal-title":"BMC Biotech."},{"key":"10.1016\/j.intimp.2022.109650_b0485","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3389\/fimmu.2019.02931","article-title":"A universal plug-and-display vaccine carrier based on HBsAg VLP to maximize effective antibody response","volume":"10","author":"Marini","year":"2019","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2022.109650_b0490","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109650_b0495","doi-asserted-by":"crossref","first-page":"e1003769","DOI":"10.1371\/journal.pmed.1003769","article-title":"Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial","volume":"18","author":"Formica","year":"2021","journal-title":"PLoS Med."},{"issue":"24","key":"10.1016\/j.intimp.2022.109650_b0500","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1016\/j.vaccine.2022.04.035","article-title":"Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: interim report of a phase I\/II randomized controlled trial","volume":"40","author":"Masuda","year":"2022","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.intimp.2022.109650_b0505","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/acsnano.0c03697","article-title":"Toward nanotechnology-enabled approaches against the COVID-19 pandemic","volume":"14","author":"Weiss","year":"2020","journal-title":"ACS Nano"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:07:20Z","timestamp":1736431640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922011353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":101,"alternative-id":["S1567576922011353"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109650","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A perspective on SARS-CoV-2 virus-like particles vaccines","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109650"}}